Table 5 Prevalence of Pfmdr1 alleles and haplotypes in day 0 (pre-treatment) and day of recurrent infection samples in the artemether-lumefantrine arm, 2018–2019 therapeutic efficacy monitoring
aPfmdr1 codon | Day 0 | Day of recurrent infection |
|---|---|---|
N86 | 128 (100%) | 127 (100%) |
86N/Y (N = 255) | 0 (0%) | 0 (0%) |
86Y | 0 (0%) | 0 (0%) |
Y184 | 48 (38%) | 38 (32%) |
Y184Y/F (N = 246) | 37 (29%) | 38 (32%) |
184F | 43 (34%) | 42 (36%) |
S1034 | 126 (100%) | 111 (100%) |
1034S/C (N = 237) | 0 (0%) | 0 (0%) |
1034C | 0 (0%) | 0 (0%) |
N1042 | 127 (100%) | 111 (100%) |
1042N/D (N = 238) | 0 (0%) | 0 (0%) |
104D | 0 (0%) | 0 (0%) |
D1246 | 116 (91%) | 107(96%) |
1246D/Y (N = 239) | 5 (4%) | 2(2%) |
1246Y | 6 (5%) | 3 (3%) |
Pfmdr1 haplotypesb | n = 127c | n = 110c |
 NFD | 78 (61%) | 76 (69%) |
 NYD | 79 (62%) | 68 (62%) |
 YFD | 0 | 0 |
 YYD | 0 | 0 |
 YYY | 0 | 0 |
 NYY | 9 (7%) | 4 (4%) |
 YFY | 0 | 0 |
 NFY | 6 (5%) | 3 (3%) |